CD274 and diffuse large B-cell lymphoma: Accordingly, the combination of atezolizumab (anti-PD-L1) plus obinutuzumab provided an ORR of 57% in patients with r/r FL, although the ORR was lower in those with r/r DLBCL (16%) [167].